THE FACT ABOUT AZELAPRAG BIOAGE THAT NO ONE IS SUGGESTING

Azelaprag was well tolerated During this study and in any way doses tested so far in 227 subjects, with a safety profile in line with the results of prior phase 1 trials conducted by Amgen., CEO of BioAge. "Given its oral availability and favorable tolerability profile, we imagine azelaprag is Preferably fitted to mixture use with incretin prescrip